382150.KQ Oncocross Co., Ltd.
- Market cap
- KRW 35.1B
- P/E
- -
- P/B
- 2.59x
- ROE
- -23.9%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 382150.KQ undervalued?
Graham numberThe Graham number of Oncocross Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oncocross Co., Ltd. fundamental analysis
3 of 21 checks passedROE 0/2
Low return on equity (-23.9%), below 10%.
ROA 0/1
Return on assets (-10.0%) is below the industry median (-3.2%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-33.9%) is below the industry median (-32.0%).
Revenue Growth 2/2
Revenue grew 35.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.0 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (2.6x) is above the industry median (1.1x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Oncocross Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oncocross Co., Ltd.
Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also…
Full company profileOncocross Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oncocross Co., Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 150M | 91.5M | 1.07B | 370M | 451M |
| Gross Profit | 34.6M | 4.51M | 1.07B | 370M | 451M |
| Operating Income | -10.00B | -6.81B | -6.96B | -8.83B | -10.4B |
| EBITDA | -9.76B | -3.63B | -6.06B | -7.59B | -437M |
| Net Income | -10.2B | -4.21B | -6.48B | -8.93B | -3.25B |
| EPS | -861 | -355 | -547 | -732 | -266 |
| Balance Sheet | |||||
| Total Assets | 8.40B | 17.6B | 22.5B | 29.0B | 32.3B |
| Total Liabilities | 3.71B | 1.10B | 2.09B | 15.6B | 18.8B |
| Shareholders' Equity | 4.70B | 16.5B | 20.5B | 13.4B | 13.6B |
| Cash & Short-term Investments | 3.19B | 11.6B | 15.3B | 2.80B | 285M |
| Cash Flow | |||||
| Operating Cash Flow | -8.20B | -4.91B | -5.52B | -7.41B | -7.49B |
| Capital Expenditure | 341M | 24.7M | 174M | 3.33B | 165M |
| Free Cash Flow | -8.54B | -4.93B | -5.70B | -10.7B | -7.66B |
| Ratios | |||||
| ROE | -217.3% | -25.6% | -31.7% | -66.8% | -23.9% |
| ROA | -121.5% | -24.0% | -28.8% | -30.8% | -10.0% |
| Net Profit Margin | -6,791.6% | -4,604.7% | -604.7% | -2,410.2% | -720.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Oncocross Co., Ltd. dividends
Oncocross Co., Ltd. has not paid dividends in the last 4 fiscal years.
Who owns Oncocross Co., Ltd.
- Insiders 16.24%
- Institutions 0.03%
- Public & others 83.73%
- Shares outstanding 12.2M
- Free float 7.27M
Oncocross Co., Ltd. company profile
- Company name
- Oncocross Co., Ltd.
- Ticker
- 382150.KQ
- Exchange
- KOSDAQ
- Sector
- Technology
- Industry
- Software - Infrastructure
- Employees
- 36
- Fiscal year end
- December
- Address
- 11, Saechang-ro, Seoul, South Korea
- Phone
- 82 2 867 9967
- Website
- oncocross.com
About Oncocross Co., Ltd.
Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular Disease; ODP9401 for metabolic disease; and ODP2201, ODP2301, and ODP2401 to treat oncology-related diseases. It has a collaboration agreement with various pharmaceutical companies, research institutes, and bio-techs. The company was founded in 2015 and is based in Seoul, South Korea.
Oncocross Co., Ltd. management
5- Dr. Yi Rang Kim M.D., Ph.D.Founder & CEO · born 1980
- Jihoon Kang M.D., Ph.D.Chief Executive Officer
- Xavier Chae M.B.A.CFO & Executive Director
- Jong Bae Park Ph.D.VP & CTO
- Dong-Myung Shin Ph.D.Head of AI Research & Executive Director